Altimmune, INC Schedule 13G passive stakes

State Street Corporation has reported beneficial ownership of 5.5% of Altimmune Inc.'s common stock as of March 31, 2026.

Viking Global Investors LP has reported a 6.7% beneficial ownership stake in Altimmune, Inc. following a recent underwritten offering.

TCG Crossover and Chen Yu have reported a combined beneficial ownership of 9.8% in Altimmune, Inc. following a recent underwritten offering.

RA Capital Management and its principals have reported a 6.5% beneficial ownership stake in Altimmune, Inc. following a recent equity offering.

Deep Track Capital and David Kroin have reported a 9.99% beneficial ownership stake in Altimmune, Inc. through common stock and warrant holdings.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Altimmune Inc. common stock following an internal realignment.

The Vanguard Group reported a 9.09% beneficial ownership stake in Altimmune Inc common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.6% beneficial ownership stake in Altimmune, Inc.'s common stock.

Ameriprise Financial, Inc. and its affiliated entities have filed an amended Schedule 13G, disclosing their beneficial ownership of Altimmune, Inc. common stock as of March 31, 2025.

Ameriprise Financial, Inc. and its affiliated entities, including Threadneedle Asset Management, have reported beneficial ownership of 7.4% of Altimmune, Inc.'s common stock as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a passive beneficial ownership of 8.7% of Altimmune, Inc.'s common stock as of December 31, 2024.